A Twenty-Four Week, Open-Label, Non-Comparative, Multi-Center Study to Assess the Efficacy and Tolerability of an Aliskiren-Based Treatment Algorithm in Patients With Mild to Moderate Hypertension.
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual patient number (256) added as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual end date (Aug 2009 ) added as reported by ClinicalTrials.gov.